Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Lung Neoplasms*/mortality ; Lung Neoplasms*/pathology ; Lung Neoplasms*/therapy ; Carcinoma, Non-Small-Cell Lung*/mortality ; Carcinoma, Non-Small-Cell Lung*/pathology ; Carcinoma, Non-Small-Cell Lung*/therapy ; Small Cell Lung Carcinoma*/mortality ; Small Cell Lung Carcinoma*/pathology ; Small Cell Lung Carcinoma*/therapy; Humans ; Germany/epidemiology ; Male ; Female ; Aged ; Middle Aged ; Neoplasm Metastasis ; Survival Rate ; Kaplan-Meier Estimate ; Aged, 80 and over ; Adult ; Immunotherapy/methods

Lung cancer is known for its high mortality; many patients already present with metastases at the time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. Population-based data, provided by the Robert-Koch Institute in Germany, was used and patients diagnosed between 2007 and 2018 were included in the study. We differentiated between NSCLC and SCLC patients and analyzed the survival over time for both sexes separately, using the Kaplan-Meier method. To evaluate survival advantages, we calculated multivariable hazard ratios. In total, 127,723 patients were considered for the study. We observed a moderate increase in survival over time. All patients showed an increased survival rate when undergoing chemotherapy. Minimal to no increase in survival was shown in NSCLC patients when receiving radiotherapy, whereas SCLC patients' survival time did benefit from it. NSCLC patients receiving immunotherapy showed an increase in survival as well. It can be concluded that advancements in radiotherapy, the application of chemotherapy, and the introduction of immunotherapies lead to an increased survival time of both NSCLC and SCLC primarily metastatic lung cancer patients.
(© 2024. The Author(s).)

Int J Cancer. 2023 Nov 15;153(10):1746-1757. (PMID: 37486208)
J Thorac Dis. 2020 Nov;12(11):6847-6853. (PMID: 33282386)
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):13-21. (PMID: 24357167)
J Cancer Res Clin Oncol. 2021 May;147(5):1325-1334. (PMID: 33569714)
N Engl J Med. 2020 Aug 13;383(7):640-649. (PMID: 32786189)
J Cancer Res Clin Oncol. 2022 May;148(5):1087-1095. (PMID: 35064816)
J Cancer Res Clin Oncol. 2021 Nov;147(11):3381-3390. (PMID: 33743072)
J Clin Oncol. 2009 Jan 1;27(1):78-84. (PMID: 19047288)
Respirology. 2020 Nov;25 Suppl 2:61-71. (PMID: 32516852)
Clin Cancer Res. 2018 Dec 1;24(23):5792-5806. (PMID: 29945993)
J Clin Oncol. 2010 Dec 10;28(35):5153-9. (PMID: 21041709)
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):7-12. (PMID: 24357166)
Curr Oncol. 2023 May 26;30(6):5299-5308. (PMID: 37366885)
J Thorac Oncol. 2007 Aug;2(8):694-705. (PMID: 17762335)
Quant Imaging Med Surg. 2018 Aug;8(7):709-718. (PMID: 30211037)
Eur J Cancer. 2015 Oct;51(15):2104-2119. (PMID: 26421815)
J Egypt Natl Canc Inst. 2007 Dec;19(4):263-74. (PMID: 19652669)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cancer Treat Res. 2016;170:47-75. (PMID: 27535389)
World J Radiol. 2012 Apr 28;4(4):128-34. (PMID: 22590666)

Keywords: Cancer registry; Germany; Lung cancer; Survival

Date Created: 20240711 Date Completed: 20240711 Latest Revision: 20240731

20240731

PMC11239887

10.1038/s41598-024-66307-3

38992115